Ting-Ting Zhao

Ting-Ting Zhao

Auto-generated profile, based on publicly available information

Ting-Ting Zhao

Institute of Immunology PLA, College of Basic Medical Sciences, Third Military Medical University, Chongqing 400038, People's Republic of China

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Vaccine
Verified
Journal Article
Closed access
GXGuilian Xu
Guilian Xu
KZKe-Qin Zhang
Ke-Qin Zhang
Bo GuoBo Guo
Bo Guo
TZTing-Ting Zhao
Ting-Ting Zhao
FYFei Yang
Fei Yang
YWYu-Zhang Wu
Yu-Zhang Wu

9 September 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
PGPingping Gao
Pingping Gao
NSNa Sun
Na Sun
NYNing Yang
Ning Yang
TZTingting Zhao
Tingting Zhao
RFRui Fu
Rui Fu
XQXiaowei Qi
Xiaowei Qi
Triple‐negative breast cancer (TNBC) remains therapeutically challenging due to its aggressive metastatic potential, high recurrence rates, and lack of effective targeted therapies. Herein, we identified that SOX30 is significantly upregulated in TNBC and correlates with poor clinical prognosis. Functionally, SOX30 specifically drives TNBC metastasis and activates the TNFR2‐mediated downstream NF‐κB signaling cascade. Mass cytometry profiling of the tumor immune microenvironment revealed that SOX30 facilitates the recruitment of tumor‐associated macrophages (TAMs) within pulmonary metastases, a finding corroborated by flow cytometric quantification. Mechanistically, downstream pathway analyses identified that SOX30 induces activation of the TNFR2–NF‐κB axis and concurrently upregulates expression of the chemokine CCL20. Therapeutic intervention with CCL20 neutralizing antibodies or small‐molecule CCR6 inhibitors effectively attenuated metastatic progression and abrogated TAM infiltration. Strikingly, combinatorial blockade using the TNFR2 inhibitor etanercept together with a CCR6 inhibitor exhibited superior anti‐metastatic efficacy relative to control treatments. Collectively, our findings delineate a novel oncogenic SOX30–TNFR2–NF‐κB–CCL20/CCR6 axis driving TNBC metastasis. These results establish SOX30 as a promising prognostic biomarker and a potential therapeutic target for anti‐metastatic strategies in TNBC.